Suppr超能文献

一项全国范围内异基因造血干细胞移植治疗成人噬血细胞性淋巴组织细胞增生症的回顾性分析。

A Nationwide Retrospective Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Hemophagocytic Lymphohistiocytosis.

机构信息

Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.

Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.

出版信息

Transplant Cell Ther. 2024 Apr;30(4):419.e1-419.e12. doi: 10.1016/j.jtct.2024.01.071. Epub 2024 Jan 22.

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening disorder characterized by systemic hyperinflammation. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative treatment for primary and relapsed/refractory HLH, the optimal strategy has not been established. We retrospectively analyzed 56 adult patients (≥18 years) with primary and secondary HLH (mainly consisting of Epstein-Barr virus-associated HLH) who underwent allo-HSCT using the registry database of the Japanese Society for Transplantation and Cellular Therapy, including 26 patients who underwent cord blood transplantation (CBT). One-fourth of patients received myeloablative conditioning (MAC), mainly consisting of total body irradiation-based regimens. The 3-year overall survival (OS) was 40.6%, while the 3-year cumulative incidences of relapse and non-relapse mortality (NRM) were 19.8% and 39.6%, respectively. In univariable analysis, age at allo-HSCT (the 3-year OS: 27.5% for ≥ 25 years old vs 58.0% for < 25 years old, P = .025), conditioning intensity (7.1% for MAC vs 51.8% for reduced-intensity conditioning (RIC), P = .002), and donor source (26.0% for CBT vs 52.9% for bone marrow or peripheral blood stem cell transplantation (BMT/PBSCT), P = .030) were associated with significantly inferior OS. In multivariable analysis, older age at allo-HSCT (≥ 25 years old) (Hazard ratio [HR], 2.37; 95% CI, 1.01 to 5.58; P = .048), MAC (HR, 2.45; 95% CI, 1.09 to 5.53; P = .031), and CBT (HR, 2.21; 95% CI, 1.04 to 4.71; P = .040) were independently associated with worse OS. In addition, only conditioning intensity predicted higher NRM (the 3-year NRM: 78.6% for MAC vs 26.6% for RIC), while no factors were associated with the relapse rate. This study includes the largest number of adult HLH patients undergoing CBT. Although the use of CBT is acceptable, BMT/PBSCT are more favorable strategies in allo-HSCT in adult HLH. Regarding conditioning intensity, RIC regimens are more beneficial in this setting.

摘要

噬血细胞性淋巴组织细胞增生症(HLH)是一种罕见的、危及生命的疾病,其特征为全身炎症反应亢进。虽然异基因造血干细胞移植(allo-HSCT)仍然是原发性和复发性/难治性 HLH 的唯一潜在治愈性治疗方法,但最佳策略尚未确定。我们使用日本移植与细胞治疗学会的注册数据库,对 56 例接受 allo-HSCT 的成人原发性和继发性 HLH(主要由 EBV 相关 HLH 组成)患者进行了回顾性分析,其中 26 例患者接受了脐带血移植(CBT)。四分之一的患者接受了清髓性预处理(MAC),主要由基于全身照射的方案组成。3 年总生存率(OS)为 40.6%,而 3 年复发率和非复发死亡率(NRM)的累积发生率分别为 19.8%和 39.6%。单变量分析显示,allo-HSCT 时的年龄(3 年 OS:≥25 岁者为 27.5%,<25 岁者为 58.0%,P =.025)、预处理强度(MAC 者为 7.1%,RIC 者为 51.8%,P =.002)和供者来源(CBT 者为 26.0%,BMT/PBSCT 者为 52.9%,P =.030)与 OS 显著相关。多变量分析显示,allo-HSCT 时年龄较大(≥25 岁)(HR,2.37;95%CI,1.01 至 5.58;P =.048)、MAC(HR,2.45;95%CI,1.09 至 5.53;P =.031)和 CBT(HR,2.21;95%CI,1.04 至 4.71;P =.040)与 OS 不良独立相关。此外,只有预处理强度预测 NRM 较高(MAC 者为 78.6%,RIC 者为 26.6%),而无其他因素与复发率相关。本研究包括了数量最多的接受 CBT 的成人 HLH 患者。尽管 CBT 的应用是可以接受的,但在成人 HLH 的 allo-HSCT 中,BMT/PBSCT 是更有利的策略。关于预处理强度,RIC 方案在该环境下更有益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验